MMP12 as a novel biomarker for progressive inflammatory kidney diseases

Project: Research

Project Details

Project Description

Macrophages are a blood-derived cell type that are known to infiltrate the kidney and cause injury. When macrophages are activated they can secrete an enzyme (called MMP12) which has the potential to induce substantial kidney injury. Recently, we found that kidney MMP12 levels are markedly increased (70-100 times) in experimental disease in which renal injury is macrophage-dependent, suggesting that monitoring MMP12 levels may have important diagnostic and prognostic value in human kidney disease. This has not previously been examined in human kidney disease. In this project, we aim to: (1) develop a reliable protocol for measuring MMP12 in patient urine samples, and (2) determine whether urine MMP12 levels correlate with MMP12 production within the kidney using analysis of renal biopsy tissue. This project will provide the critical preliminary data required for a future large scale study of the diagnostic and prognostic significance of urine MMP12 levels as a biomarker in different types of human kidney disease. It is anticipated that high levels of urine MMP12 will be associated with the presence of activated macrophages within the kidney, and that such patients will be responsive to aggressive immunosuppressive therapy to target macrophage activation. Furthermore, the ultimate aim of these studies is to determine whether we should target the activity of MMP12 itself as a novel therapy in the treatment of inflammatory kidney disease.
Kidney Health Australia Seeding Grant: AU$15000
Effective start/end date24/10/0724/10/08